Conflict of interest None declared.
A new therapeutic option for facial seborrhoeic dermatitis: indole-3-acetic acid photodynamic therapy
Article first published online: 10 JAN 2013
© 2013 The Authors. Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 1, pages 94–99, January 2014
How to Cite
Kwon, S.H., Jeong, M.Y., Park, K.C., Youn, S.W., Huh, C.H. and Na, J.I. (2014), A new therapeutic option for facial seborrhoeic dermatitis: indole-3-acetic acid photodynamic therapy. Journal of the European Academy of Dermatology and Venereology, 28: 94–99. doi: 10.1111/jdv.12070
Funding sources Seoul National University Bundang Hospital Research Fund (02-2011-040).
- Issue published online: 17 DEC 2013
- Article first published online: 10 JAN 2013
- Received: 9 October 2012; Accepted: 15 November 2012
- Seoul National University Bundang Hospital Research Fund. Grant Number: 02-2011-040
Background Indole-3-acetic acid (IAA) is a newly introduced photosensitizer of photodynamic therapy (PDT) for acne, presenting sebum-reducing, anti-inflammatory and antimicrobial activity.
Objective This study was designed to evaluate the efficacy and safety of IAA-PDT in the treatment of facial seborrhoeic dermatitis.
Method In this prospective, single-blinded, 6-week trial, 23 patients with facial seborrhoeic dermatitis were treated with IAA-PDT with green light (520 nm) three times with 1-week intervals. Patients were evaluated at baseline, week 1, 2, 3 and week 6 (3 weeks after last treatment). Efficacy was determined by Seborrhoeic dermatitis Area and Severity Index (SASI), patient’s assessment of the symptoms (4-point scale of itchiness, burning, erythema, scale and tightness), sebum secretion rate (measured with Sebumeter®), Erythema Index (EI, measured with Mexameter®) and physician’s photographic assessment. Safety was evaluated by questionnaire at each visit.
Result For the 22 subjects completing the trial, SASI and total symptom significantly improved at week 2, which lasted until week 6. Sebum excretion was significantly reduced at week 2 and stayed reduced until week 6. EI presented continuous reduction throughout the study. Photographic assessment showed significant improvement at each visit. The procedure was painless, and no adverse event was observed during and after the treatment.
Conclusion IAA-PDT is a safe and effective therapeutic option for facial seborrhoeic dermatitis.